Pertuzumab and trastuzumab (Phesgo®) is licensed for the following therapeutic indications:
- Early breast cancer: is indicated for use in combination with chemotherapy in
- The neoadjuvant treatment of adult patients with HER2-positive, locally advanced, inflammatory or early stage breast cancer at high risk of recurrence
- The adjuvant treatment of adult patients with HER2-positive early breast cancer at high risk of recurrence
- Metastatic breast cancer: is indicated for use in combination with docetaxel in adult patients with HER2-positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti-HER2 therapy or chemotherapy for their metastatic disease.
| Assessment Status | Rapid Review Complete |
| HTA ID | 20053 |
| Drug | Pertuzumab and trastuzumab |
| Brand | Phesgo® |
| Indication | For the treatment of Early breast cancer and Metastatic breast cancer |
| Assessment Process | |
| Rapid review commissioned | 07/12/2020 |
| Rapid review completed | 06/01/2021 |
| Rapid review outcome | A full HTA is not recommended. The NCPE recommends that pertuzumab and trastuzumab (Phesgo®) not be considered for reimbursement at the submitted price*. |
* This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods Act) 2013.
The HSE has approved reimbursement following confidential price negotiations (December 2022) for the for the following indications:
• In combination with chemotherapy in the neoadjuvant treatment of adult patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer at high risk of recurrence
• and in combination with Docetaxel in adult patients with HER2-positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti-HER2 therapy or chemotherapy for their metastatic disease.
Pertuzumab / trastuzumab (Phesgo®) for the adjuvant treatment of adult patients with HER2-positive early breast cancer at high risk of recurrence is not currently reimbursed by the HSE.
